Olympiad Research LP Invests $262,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Olympiad Research LP bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,242 shares of the company’s stock, valued at approximately $262,000.

Other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the period. Van ECK Associates Corp purchased a new position in Hims & Hers Health during the second quarter worth about $111,000. CWM LLC raised its holdings in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank raised its holdings in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the sale, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 854,547 shares of company stock valued at $15,987,230 in the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Truist Financial increased their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. TD Cowen increased their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Hims & Hers Health Price Performance

Shares of HIMS opened at $23.62 on Friday. The firm has a 50 day simple moving average of $18.40 and a 200-day simple moving average of $18.29. Hims & Hers Health, Inc. has a 1-year low of $6.58 and a 1-year high of $25.74. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 54.80 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period last year, the company posted ($0.04) EPS. The company’s revenue was up 77.1% on a year-over-year basis. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.